{"id":883002,"date":"2025-09-06T22:19:35","date_gmt":"2025-09-07T02:19:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/icecures-prosense-substantially-reduces-abdominal-wall-endometriosis-pain-with-high-procedural-efficacy\/"},"modified":"2025-09-06T22:19:35","modified_gmt":"2025-09-07T02:19:35","slug":"icecures-prosense-substantially-reduces-abdominal-wall-endometriosis-pain-with-high-procedural-efficacy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/icecures-prosense-substantially-reduces-abdominal-wall-endometriosis-pain-with-high-procedural-efficacy\/","title":{"rendered":"IceCure’s ProSense\u00ae Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had\u00a0ProSense\u00ae cryoablation procedures <\/i>
\n <\/b>\n <\/p>\n

\n
\n ProSense\u00ae is FDA cleared and approved in the European Union for gynecological indications<\/i>
\n <\/b>\n <\/p>\n

\n
\n CAESAREA, Israel<\/span>
\n <\/span>, Sept. 4, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0IceCure Medical Ltd.<\/a> (NASDAQ<\/span>: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced encouraging findings from a recently published, independently conducted study evaluating the efficacy and safety of personalized percutaneous single-probe liquid-nitrogen cryoablation with ProSense\u00ae in treating symptomatic abdominal wall endometriosis (“AWE”).<\/p>\n

\n \"IceCure\n <\/div>\n

AWE is a debilitating condition, often occurring in surgical scars after caesarean sections. It is characterized by cyclic pain and a palpable mass, significantly impacting the quality of life of the individual. Traditional treatments, including hormonal therapy and surgery, have their limitations, which has prompted interest in minimally invasive techniques such as cryoablation.<\/p>\n

The peer-reviewed study<\/a>, published in Journal of Personalized Medicine, titled “Efficacy and Safety of Percutaneous Single-Probe Cryoablation Using Liquid Nitrogen in the Treatment of Abdominal Wall Endometriosis,” was conducted at N\u00eemes University Hospital in N\u00eemes, France<\/span>. The study enrolled 14 patients with a total of 23 AWE lesions, who were treated between September 2022<\/span> and April 2025<\/span>.<\/p>\n

“We are very pleased to share the results of this independent study which concluded that percutaneous cryoablation with ProSense\u00ae is a safe and effective minimally invasive cryosurgical tool for abdominal wall endometriosis, offering significant pain relief and excellent cosmetic outcomes,” stated IceCure’s Chief Executive Officer, Eyal Shamir<\/span>. The researchers went on to state it should be considered as part of multidisciplinary care for women with AWE. Evidence of ProSense\u00ae’s efficacy in multiple gynecological indications further supports its commercial potential and momentum.<\/p>\n

Key Study Highlights include the following:<\/p>\n